$SENS 
Recent Developments 
· Fourth quarter 2020 net revenue is expected to be approximately $3.5 million, increased from the prior expectation of approximately $2.5 million
· Received communication from the FDA explaining the reallocation of agency resources to address Emergency Use Authorization (EUA) applications for products related to the COVID-19 public health emergency is affecting marketing application reviews, including the Eversense 180-day product, which will be delayed by at least 60 days. This is consistent with what Senseonics understands other medical technology companies have reported.
· Inclusion of Eversense Category III CPT codes in the Centers for Medicare &amp; Medicaid Services (CMS) 2021 Physician Fee Schedule (PFS), establishing global payment for the device cost and procedure fees for healthcare providers across the United States
· Full year 2021 net revenue is expected to be between $12 and $15 million, based on installed base, acceleration of Ascensia’s 
 .....
<ticker> recent developments fourth quarter <number> net revenue is expected to be approximately $ <number> million , increased from the prior expectation of approximately $ <number> million received communication from the fda explaining the reallocation of agency resources to address emergency use authorization eua applications for products related to the covid - <number> public health emergency is affecting marketing application reviews , including the eversense <number> - day product , which will be delayed by at least <number> days . this is consistent with what <company> understands other medical technology companies have reported . inclusion of eversense category ii <ticker> codes in the centers for medicare & medicaid services <ticker> <number> physician fee schedule <ticker> establishing global payment for the device cost and procedure fees for healthcare providers across the united states full year <number> net revenue is expected to be between $ <number> and $ <number> million , based on installed base , acceleration of ascensias  . .